We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App




Molecular Multiplexing Panel for Blood Culture Identification Enables Targeted Treatment Decisions

By LabMedica International staff writers
Posted on 03 Oct 2024
Print article
Image: The LIAISON PLEX Gram-Negative Blood Culture Assay runs on the on the LIAISON PLEX instrument (Photo courtesy of Diasorin)
Image: The LIAISON PLEX Gram-Negative Blood Culture Assay runs on the on the LIAISON PLEX instrument (Photo courtesy of Diasorin)

Each year, approximately 250,000 patients in the US are diagnosed with bloodstream infections (BSIs). Sepsis resulting from BSIs has an average mortality rate of 16-40%, and any delays in initiating appropriate treatment increase patient risk. Sepsis is also the most expensive cause of hospitalization in the US, accounting for more than USD 20 billion annually. Gram-negative bacteremia represents about 30% of all positive blood cultures, and each pathogen along with its resistance genes often necessitates adjustments to the initial empiric therapy. Now, a multiplex blood culture panel can improve the microbiological diagnosis of BSIs by detecting Gram-negative bacteria and relevant resistance genes, thereby enhancing standard-of-care workflows and reducing operational costs.

Diasorin’s (Saluggia VC, Italy) LIAISON PLEX Gram-Negative Blood Culture Assay enables clinicians to make more targeted treatment decisions within two hours after the Gram stain by quickly identifying pathogens and detecting resistance determinants. The assay utilizes Diasorin’s proprietary NanoGrid technology, a unique non-amplified molecular chemistry designed to reduce false positives. Because this panel is based on Gram stain results and focuses exclusively on Gram-negative pathogens, it enhances diagnostic stewardship and helps control treatment costs compared to current market solutions that include a broader range of pathogens associated with bacteremia, regardless of Gram stain results.

Diasorin has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the LIAISON PLEX Gram-Negative Blood Culture Assay, which is the second of three molecular multiplex panels for blood culture identification on the LIAISON PLEX instrument. Previously, Diasorin received FDA clearance for the LIAISON PLEX Respiratory Flex Assay in March 2024 and the LIAISON PLEX Yeast Blood Culture Assay in June 2024.

“We firmly believe that LIAISON PLEX provides unique flexibility by enabling clinicians to select the most appropriate blood panel for their patients. This ensures that clinical laboratories can generate reliable results more quickly and cost-effectively,” said Angelo Rago, President of Luminex. “We are committed to developing critically important tests for the platform to expand its application to a broader range of healthcare needs.”

Related Links:
Diasorin

New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Quantitative Immunoassay Analyzer
AS050
New
Silver Member
Rubella Infection ELISA
ReQuest RUBELLA IgM ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Immunology

view channel
Image: An immune response is initiated when an antigen-presenting cell (pink) presents foreign material to a T-cell (blue) (Photo courtesy of JAX)

Advanced Imaging Method Maps Immune Cell Connections to Predict Cancer Patients Survival

A growing tumor is influenced not only by the tumor cells themselves but also by the surrounding tissue, which alters its biology. Immune cells communicate by transferring vital signaling proteins to their... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: LMU’s Professor Frederick Klauschen developed the novel approach that can improve diagnostic accuracy (Photo courtesy of LMU Munich)

AI Tool Uses Imaging Data to Detect Less Frequent GI Diseases

Artificial intelligence (AI) is already being utilized in various medical fields, demonstrating significant potential in aiding doctors in diagnosing diseases through imaging data. However, training AI... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.